Concert Pharmaceuticals, which is developing novel small molecule drugs for the treatment of spasticity and diabetic kidney disease, filed on Monday with the SEC to raise up to $75 million in an initial public offering. The Lexington, MA-based company, which was founded in 2006 and booked $24 million in license and milestone revenue for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol CNCE. UBS Investment Bank and Wells Fargo Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
